公开(公告)号：US20060057205A1

公开(公告)日：2006-03-16

申请号：US10939351

申请日：2004-09-14

申请人： Viswanathan Srinivasan ,  Raph Brown ,  David Brown ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud

发明人： Viswanathan Srinivasan ,  Raph Brown ,  David Brown ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud

IPC分类号： A61K31/485 ,  A61K31/137 ,  A61K9/24

CPC分类号： A61K45/06 ,  A61K9/209 ,  A61K31/137 ,  A61K31/485 ,  A61K2300/00

摘要： A pharmaceutical dosage form which comprises phenylepherine or a pharmaceutically acceptable salt thereof and a second drug. The dosage form provides a plasma concentration within the therapeutic range of the second drug over a period which is coextensive with at least about 70% of the period over which the dosage form provides a plasma concentration within the therapeutic range of phenylepherine. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

摘要翻译： 一种药物剂型，其包含苯乙醇或其药学上可接受的盐和第二种药物。 该剂型在第二药物的治疗范围内提供血浆浓度，该时间段与至少约70％的期间共同延长，在该时间内，剂型提供在苯乙醇的治疗范围内的血浆浓度。 该摘要既不旨在限定本说明书中公开的发明，也不旨在以任何方式限制本发明的范围。

公开(公告)号：US20070003622A1

公开(公告)日：2007-01-04

申请号：US11102726

申请日：2005-04-11

申请人： Viswanathan Srinivasan ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud ,  Ralph Brown ,  David Brown

发明人： Viswanathan Srinivasan ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud ,  Ralph Brown ,  David Brown

IPC分类号： A61K9/24

CPC分类号： A61K9/10 ,  A61K9/209 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

摘要： A pharmaceutical dosage form which comprises diphenhydramine and/or a pharmaceutically acceptable salt thereof. The dosage form is capable of providing a diphenhydramine plasma concentration within a therapeutic range for at least about 24 hours per single dose. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

摘要翻译： 包含苯海拉明和/或其药学上可接受的盐的药物剂型。 该剂型能够将治疗范围内的苯海拉姆血浆浓度提供至少约24小时/单次剂量。 本摘要既不旨在限定本说明书中公开的发明，也不旨在以任何方式限制本发明的范围。

公开(公告)号：US20060134207A1

公开(公告)日：2006-06-22

申请号：US11012267

申请日：2004-12-16

申请人： Viswanathan Srinivasan ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud ,  Ralph Brown ,  David Brown

发明人： Viswanathan Srinivasan ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud ,  Ralph Brown ,  David Brown

IPC分类号： A61K31/485 ,  A61K9/22

CPC分类号： A61K9/10 ,  A61K9/209 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

摘要： A pharmaceutical dosage form which comprises diphenhydramine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period over which the dosage form provides a plasma concentration within the therapeutic range of diphenhydramine or salt thereof. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

摘要翻译： 包含苯海拉明和/或其药学上可接受的盐和至少一种第二种药物的药物剂型。 所述剂型在与所述剂型在苯海拉明或其盐的治疗范围内提供血药浓度的相当长的一段时间内共同延长的时期内提供至少一种第二药物的治疗范围内的血浆浓度。 本摘要既不旨在限定本说明书中公开的发明，也不旨在以任何方式限制本发明的范围。

公开(公告)号：US20060029664A1

公开(公告)日：2006-02-09

申请号：US10910806

申请日：2004-08-04

申请人： Viswanathan Srinivasan ,  Ralph Brown ,  David Brown ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud

发明人： Viswanathan Srinivasan ,  Ralph Brown ,  David Brown ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud

IPC分类号： A61K9/20

CPC分类号： A61K9/209 ,  A61K9/0095

摘要： A pharmaceutical dosage form which comprises carbetapentane and/or a pharmaceutically acceptable salt thereof and an additional drug. The dosage form provides a plasma concentration within the therapeutic range of the additional drug over a period which is coextensive with at least about 70% of the period over which the dosage form provides a plasma concentration within the therapeutic range of carbetapentane. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

摘要翻译： 包含碳代戊烷和/或其药学上可接受的盐和另外的药物的药物剂型。 所述剂型在额外药物的治疗范围内提供血浆浓度，所述时间段与至少约70％的剂型共同延长的时间段内，所述剂型在该时间段内提供血浆浓度在碳卡巴坦的治疗范围内。 该摘要既不旨在限定本说明书中公开的发明，也不旨在以任何方式限制本发明的范围。

公开(公告)号：US20050266032A1

公开(公告)日：2005-12-01

申请号：US11115321

申请日：2005-04-27

申请人： Viswanathan Srinivasan ,  Ralph Brown ,  David Brown ,  Himanshu Patel ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud

发明人： Viswanathan Srinivasan ,  Ralph Brown ,  David Brown ,  Himanshu Patel ,  Juan Menendez ,  Venkatesh Balasubramanian ,  Somphet Suphasawud

IPC分类号： A61K31/137 ,  A61K31/485

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/485 ,  A61K2300/00

摘要： A pharmaceutical dosage form comprising a first drug and a second drug, both of which are selected from decongestants, antitussives, expectorants, analgesics and antihistamines. The dosage form provides a plasma concentration within a therapeutic range of the second drug over a period which is coextensive with at least about 70% of a period over which the dosage form provides a plasma concentration within a therapeutic range of the first drug. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

摘要翻译： 一种包含第一药物和第二药物的药物剂型，它们都选自减充血剂，镇咳药，祛痰剂，止痛剂和抗组胺剂。 剂型提供在第二药物的治疗范围内的血浆浓度，其在与第一药物的治疗范围内提供血浆浓度的至少约70％的期间共同延长的时期内。 本摘要既不旨在限定本说明书中公开的发明，也不旨在以任何方式限制本发明的范围。

公开(公告)号：US20050232987A1

公开(公告)日：2005-10-20

申请号：US10798884

申请日：2004-03-12

申请人： Viswanathan Srinivasan ,  Ralph Brown ,  David Brown ,  Himanshu Patel ,  Juan Menendez ,  Venkatesh Balasubramanian

发明人： Viswanathan Srinivasan ,  Ralph Brown ,  David Brown ,  Himanshu Patel ,  Juan Menendez ,  Venkatesh Balasubramanian

IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K9/24 ,  A61K31/137 ,  A61K31/485

CPC分类号： A61K9/2077 ,  A61K9/209 ,  A61K31/137 ,  A61K31/485 ,  A61K2300/00

摘要： A pharmaceutical dosage form which comprises a first drug which comprises at least one morphine derivative with antitussive activity and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with at least about 70% of the period over which the dosage form provides a plasma concentration within the therapeutic range of the first drug. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

摘要翻译： 一种药物剂型，其包含含有至少一种具有镇咳活性的吗啡衍生物和至少一种第二药物的第一药物。 所述剂型在所述至少一种第二药物的治疗范围内提供血浆浓度，所述时间段与至少约70％的所述时间段共同延长的时间段内，所述剂型在该时间段内提供在第一药物的治疗范围内的血浆浓度 。 该摘要既不旨在限定本说明书中公开的发明，也不旨在以任何方式限制本发明的范围。

公开(公告)号：US09592197B2

公开(公告)日：2017-03-14

申请号：US11012267

申请日：2004-12-16

申请人： Viswanathan Srinivasan ,  Juan Carlos Menendez ,  Venkatesh Balasubramanian ,  Somphet Peter Suphasawud ,  Ralph Brown ,  David Brown

发明人： Viswanathan Srinivasan ,  Juan Carlos Menendez ,  Venkatesh Balasubramanian ,  Somphet Peter Suphasawud ,  Ralph Brown ,  David Brown

IPC分类号： A61K9/20 ,  A61K9/10 ,  A61K9/24 ,  A61K31/485 ,  A61K45/06

CPC分类号： A61K9/10 ,  A61K9/209 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

摘要： A pharmaceutical dosage form which comprises diphenhydramine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period over which the dosage form provides a plasma concentration within the therapeutic range of diphenhydramine or salt thereof. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

摘要翻译： 包含苯海拉明和/或其药学上可接受的盐和至少一种第二种药物的药物剂型。 所述剂型在与所述剂型在苯海拉明或其盐的治疗范围内提供血药浓度的相当长的一段时间内共同延长的时期内提供至少一种第二药物的治疗范围内的血浆浓度。 本摘要既不旨在限定本说明书中公开的发明，也不旨在以任何方式限制本发明的范围。

公开(公告)号：US09492541B2

公开(公告)日：2016-11-15

申请号：US10939351

申请日：2004-09-14

申请人： Viswanathan Srinivasan ,  Ralph Brown ,  David Brown ,  Juan Carlos Menendez ,  Venkatesh Balasubramanian ,  Somphet Peter Suphasawud

发明人： Viswanathan Srinivasan ,  Ralph Brown ,  David Brown ,  Juan Carlos Menendez ,  Venkatesh Balasubramanian ,  Somphet Peter Suphasawud

IPC分类号： A61K9/20 ,  A61K31/137 ,  A61K45/06 ,  A61K9/24 ,  A61K31/485

CPC分类号： A61K45/06 ,  A61K9/209 ,  A61K31/137 ,  A61K31/485 ,  A61K2300/00

摘要： A pharmaceutical dosage form which comprises phenylepherine or a pharmaceutically acceptable salt thereof and a second drug. The dosage form provides a plasma concentration within the therapeutic range of the second drug over a period which is coextensive with at least about 70% of the period over which the dosage form provides a plasma concentration within the therapeutic range of phenylepherine. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

公开(公告)号：US20120201887A1

公开(公告)日：2012-08-09

申请号：US13021240

申请日：2011-02-04

申请人： Nils Ahlgren ,  Mark Nuttall ,  Jeannie Wong ,  Venkatesh Balasubramanian ,  Craig Belongie ,  Ashfaq Khan ,  Neil Campbell Muir

发明人： Nils Ahlgren ,  Mark Nuttall ,  Jeannie Wong ,  Venkatesh Balasubramanian ,  Craig Belongie ,  Ashfaq Khan ,  Neil Campbell Muir

IPC分类号： A61K9/24 ,  A61K31/795 ,  A61K31/785 ,  A61K31/787 ,  A61P11/14 ,  A61K31/485 ,  A61K9/30 ,  A61P11/00 ,  A61P11/02 ,  A61K31/09 ,  A61K9/22

CPC分类号： A61K31/09 ,  A61K9/20 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K31/137 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

摘要： A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.

摘要翻译： 一种片剂形式的药物组合物，包括第一部分和第二部分，其中所述第一部分包括立即释放曲线的愈创甘油醚和具有持续释放曲线的第二药物，其中第二部分包括持久释放的愈创甘油醚 个人资料 第二种药物可以是药物 - 树脂复合物的形式。 第二种药物可以是抗咳嗽或减充血剂。 药物 - 树脂复合物包括与离子交换树脂络合的药物。 离子交换树脂可以是聚苯乙烯磺酸酯树脂，聚乙烯树脂，聚丙烯酸钾，考来烯胺树脂或考来烯胺树脂。 药物 - 树脂复合物可以设置有涂层，选择涂层厚度以获得所需的释放曲线。 药物 - 树脂复合物可以具有5％至50％的包衣水平。 涂层水平可以为10％至35％。

公开(公告)号：US20080069339A1

公开(公告)日：2008-03-20

申请号：US11509361

申请日：2006-08-24

申请人： Nasima Parveen ,  Venkatesh Balasubramanian

发明人： Nasima Parveen ,  Venkatesh Balasubramanian

IPC分类号： H04L9/28

CPC分类号： G09C1/00 ,  H04L9/0631 ,  H04L9/0637 ,  H04L2209/12

摘要： An apparatus comprising a mode circuit and an encryption circuit. The mode circuit may be configured to selectively provide register input data on an output signal when in a first mode and memory data on the output signal when in a second mode. The encryption circuit may be configured to interchangeably encrypt/decrypt between the register input data and the memory data.

摘要翻译： 一种包括模式电路和加密电路的装置。 模式电路可以被配置为当处于第一模式时在输出信号上选择性地提供寄存器输入数据，并且当处于第二模式时，输出信号上的存储器数据。 加密电路可以被配置为在寄存器输入数据和存储器数据之间可互换地加密/解密。